Skip to main content

Drug Interactions between abacavir / dolutegravir / lamivudine and Emtriva

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

lamiVUDine emtricitabine

Applies to: abacavir / dolutegravir / lamivudine and Emtriva (emtricitabine)

GENERALLY AVOID: Concomitant use of the cytidine analog nucleoside reverse transcriptase inhibitors (NRTI) lamivudine and emtricitabine may inhibit the intracellular phosphorylation of one another to their respective active derivative in vivo. This could result in diminished antiretroviral effects of these drugs. However, clinical experience on the coadministration of cytidine analogs is lacking. This interaction may also occur with zalcitabine. In addition, the therapeutic efficacy of these drugs in combination appears limited, since lamivudine and emtricitabine have similar resistance profiles via mutation of the same viral reverse transcriptase gene (M184V).

MANAGEMENT: The use of the cytidine analog NRTIs lamivudine, emtricitabine, or zalcitabine in any combination in an antiretroviral treatment regimen that consists of two NRTIs is not recommended. Local antiretroviral treatment experts should be consulted for current practice.

References

  1. "Product Information. Epivir (lamivudine)." Glaxo Wellcome PROD (2001):
  2. Veal GJ, Hoggard PG, Barry MG, Khoo S, Back DJ "Interaction between lamivudine (3TC) and other nucleoside analogues for intracellular phosphorylation." AIDS 10 (1996): 546-8
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  4. Cerner Multum, Inc. "Australian Product Information." O 0
  5. Department of Health and Human Services "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. https://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultAndAdolescentGL.pdf" (2015):
View all 5 references

Switch to consumer interaction data

Drug and food interactions

Minor

dolutegravir food

Applies to: abacavir / dolutegravir / lamivudine

Food increases the extent of absorption and slows the rate of absorption of dolutegravir. When administered with a low-, moderate- or high-fat meal, dolutegravir peak plasma concentration (Cmax) increased by 46%, 52% and 67%, systemic exposure (AUC) increased by 33%, 41% and 66%, and time to reach Cmax (Tmax) increased from 2 hours to 3, 4 and 5 hours, respectively, compared to administration under fasted conditions. Dolutegravir may be taken with or without food.

References

  1. "Product Information. Tivicay (dolutegravir)." ViiV Healthcare (2013):

Switch to consumer interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer